Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 20/100

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Key Takeaway: Corcept Therapeutics is facing a class-action lawsuit after allegedly failing to disclose crucial information regarding its product candidate, relacorilant, during a specified period. The lawsuit follows the FDA's issuance of a Complete Response Letter, stating the need for more evidence to assess the drug's effectiveness. As a result, the company’s share price fell by more than 50% in a single day. Investors impacted by the drop have until April 21, 2026, to apply as lead plaintiffs in the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept Therapeutics faces a class-action lawsuit due to failing to disclose material information.
  • The company's share price dropped by over 50% following the FDA's negative response on relacorilant's NDA.
  • Investors with losses over $100,000 are encouraged to file lead plaintiff applications.

Full Press Release Details

NEW ORLEANS, April 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Corcept investors should visit us at https://claimsfiler.com/cases/nasdaq-cort-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.
The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

Investors must file by April 21, 2026.

What period does the Corcept lawsuit cover?

The class period is from October 31, 2024, to December 30, 2025.

Why is Corcept facing a class action lawsuit?

They allegedly failed to disclose important information affecting stock value.

What did the FDA's Complete Response Letter indicate?

It revealed additional evidence of relacorilant's effectiveness was required.

Where can Corcept investors find more information?

Visit https://claimsfiler.com/cases/nasdaq-cort-1/ or call 844-367-9658.

Last updated: Apr 9, 2026